Shanghai Pharmaceuticals Holding Co., Ltd.

Chinese Academy of Sciences

Shanghai Institutes for Biological Sciences, Cas

Gang Pei

Jing Lu

Biao Yu

Yue Ming Zhou

Xin Cao

Shichao Huang

Fuchun Shi

Yuqian An

Jian Zhao

Xiaohui Zhao

Bing Luan

Yanxiang Ni

The present invention relates to a novel therapeutic drug for a neurodegenerative disease and an application thereof. Provided is a novel compound of formula (I). The compound can effectively facilitate the proliferation of neural stem cells in both in vitro and in vivo experiments and can be used as a treatment approach for facilitating neuroregeneration to fight against cognitive decline associated with aging or a neurodegenerative disease.

Therapeutic drug for neurodegenerative disease and application thereof

The present invention relates to a novel compound for preventing or treating neurodegenerative diseases and use thereof. Provided is a novel compound of Formula (I). The compound can effectively promotes the proliferation of neural progenitor cells in both in vitro and in vivo experiments, and can serves as a treatment approach to promote nerve regeneration to fight against cognition impairment associated with aging and neurodegenerative diseases.

Compound for preventing or treating neurodegenerative disease and application thereof

The present invention provides the use of &#x3b2;arrestin2 protein or its up-regulators for manufacturing a composition for the prevention or treatment of insulin resistance or related disease in mammals. The reagents and the kits for the specific identification of &#x3b2;arrestin2 protein or its coding gene or transcript are also provided which can be used in diagnosis of insulin resistance or related diseases.

Methods and reagents for the diagnosis, prevention and treatment of insulin resistance using beta-arrestin2 and its up-regulators

A method for screening a reagent for treating or preventing Alzheimer's disease or related neurological pathology includes the steps of: (a) activating a receptor and determining a first extent of endocytosis of the receptor, wherein the receptor is a G-protein coupled receptor that associates with presenilin-1; (b) activating the receptor under the same conditions as in step (a), in the presence of a candidate reagent, and determining a second extent of endocytosis of the receptor; (c) determining a difference between the first extent of endocytosis and the second extent of endocytosis; and (d) repeating steps (a)-(c), if the difference is less than a threshold. Uses of receptor antagonists for manufacturing medicaments for treating or preventing Alzheimer's disease or related neurological pathology, wherein the receptor antagonists inhibit endocytosis of a G-protein coupled receptor that associates with presenilin-1 during endocytosis.

Screening G protein-coupled receptor antagonists for methods of treating Alzheimer's disease

Growing community of inventors

Shanghai, China

Gang Pei